1470. Linezolid for Treatment of Urinary Tract Infections Caused by Vancomycin-resistant Enterococci
Benjamin Pontefract, PharmD, BCPS; Karl Madaras-Kelly, PharmD, MPH; Boise VA Medical Center, Boise, Idaho; 2Idaho State University, Boise, Idaho
Session: 157. Urinary Tract Infections
Friday, October 4, 2019: 12:15 PM
Background. Urinary tract infections (UTI) caused by vancomycin-resistant enterococcus (VRE) are difficult to manage due to lack of effective oral treatment options. Linezolid is an antibiotic with activity against VRE that is available orally, but only 30% of each dose is excreted in the urine. Data on the efficacy of linezolid in the treatment of UTI is limited. The purpose of this analysis was to assess the comparative efficacy of linezolid to other VRE-active antibiotics in the treatment of UTI.

Methods. A national retrospective cohort of inpatient veterans with a positive urine culture for VRE during years 2013 through 2018 was developed. Patient demographics, vital signs, urinary symptoms, antibiotics prescribed, and 14-day post-treatment outcomes were collected. Patients without UTI symptoms, urine cultures with <10^2 CFU/mL (≤10^2 CFU/mL for catheterized patients), or patients not treated with VRE-active antibiotics were excluded. Odds ratios were used to compare linezolid and non-linezolid antibiotics for 14-day VRE bacteriuria, UTI retreatment, and death endpoints.

Results. Of 3,846 urine cultures identified with VRE, 624 (16%) patients were eligible for evaluation of UTI symptoms. Of these, 92/624 (15%) met study criteria. The primary reason for exclusion was asymptomatic bacteriuria [339/532 (64%)]. Linezolid was prescribed in 54/592 (9%) of cases. Controls included penicillin [12/92 (13%),] nitrofurantoin [11/92 (12%),] daptomycin [7/92 (8%),] tetracyclines [6/92 (7%),] and others [2/92 (2%)]. Between linezolid and comparator groups, mean (+S.D.) patient age [70 (12) vs. 68 (13) years, P = 0.45] and Charlson Comorbidity Index [8.9 (3.1) vs. 8.3 (3.5), P = 0.39] were similar. Negative outcomes were uncommon: 7% VRE bacteriuria, 8% UTI re-treatment, 4% death. No difference in [OR] (+S.D.) patient age [70 (12) vs. 68 (13) years, P = 0.45] and Charlson Comorbidity Index [8.9 (3.1) vs. 8.3 (3.5), P = 0.39] were similar. Negative outcomes were uncommon: 7% VRE bacteriuria, 8% UTI re-treatment, 4% death. No difference in

Conclusion. Most patients with a VRE positive urine culture who received antibiotics for UTI symptoms fulfilled diagnostic criteria for UTI, and negative outcomes were uncommon. Linezolid and comparator regimens with VRE activity were effective for treating mild VRE UTI.

Disclosures. All authors: No reported disclosures.

1471. Medical Claims Analysis as a Tool to Evaluate Empiric and Targeted Antibiotic Therapy in UTIs
Wing Hui MS, Nuno T. Antunes, PhD; Shriram Veeramani, MS; David Holman, PhD; Decision Resources Group, Toronto, ON, Canada
Session: 157. Urinary Tract Infections
Friday, October 4, 2019: 12:15 PM
Background. Empiric therapy is a mainstay of the inpatient management of urinary tract infections (UTIs), and the choice of empiric antibiotic is shaped by local epidemiology and patient risk factors and comorbidities. Pathogen identification (ID) and antibiotic susceptibility testing (AST) provide information that can guide adjustments in therapy, allowing de-escalation to more targeted, narrow-spectrum antibiotics.

Methods. Real-world data (hospital billing claims) from 2017 was used to extract relevant information. Retrospective analysis on inpatients with bacterial UTIs utilizing cUTI. We included a “structured patient interview (SPI)” while conducting a patient-reported outcomes (PRO) measures are recommended in clinical study designs for certain indications to evaluate response to therapy from the patient’s perspective, and a PRO was recommended for the final completed urine tract infection (cUTI) guidance in 2014. Several PRO tools have been rigorously validated, but currently, no tool exists for evaluating cUTI. We included a “structured patient interview (SPI)” while conducting a randomized, double-blind, study (NCCT0231800) investigating cefiderocol (CFDC) vs. piperacillin–tazobactam (TZP) (80/50%), C. A. E. coli showed higher sensitivity to amikacin and TZP compared with H. A. O. coli. C. A. K. pneumoniae showed much higher sensitivity to TZP compared with H. A. K. pneumoniae. Of total ESBL-E, the antimicrobial resistance rate to aminoglycoside such as amikacin and gentamicin showed full sensitivity over the years.

Results. Of 3,846 urine cultures identified with VRE, 624 (16%) patients were eligible for evaluation of UTI symptoms. Of these, 92/624 (15%) met study criteria. The primary reason for exclusion was asymptomatic bacteriuria [339/532 (64%)]. Linezolid was prescribed in 54/592 (9%) of cases. Controls included penicillin [12/92 (13%),] nitrofurantoin [11/92 (12%),] daptomycin [7/92 (8%),] tetracyclines [6/92 (7%),] and others [2/92 (2%)]. Between linezolid and comparator groups, mean (+S.D.) patient age [70 (12) vs. 68 (13) years, P = 0.45] and Charlson Comorbidity Index [8.9 (3.1) vs. 8.3 (3.5), P = 0.39] were similar. Negative outcomes were uncommon: 7% VRE bacteriuria, 8% UTI re-treatment, 4% death. No difference in [OR] (+S.D.) patient age [70 (12) vs. 68 (13) years, P = 0.45] and Charlson Comorbidity Index [8.9 (3.1) vs. 8.3 (3.5), P = 0.39] were similar. Negative outcomes were uncommon: 7% VRE bacteriuria, 8% UTI re-treatment, 4% death. No difference in

Conclusion. Most patients with a VRE positive urine culture who received antibiotics for UTI symptoms fulfilled diagnostic criteria for UTI, and negative outcomes were uncommon. Linezolid and comparator regimens with VRE activity were effective for treating mild VRE UTI.

Disclosures. All authors: No reported disclosures.

1474. Epidemiology and Outcomes of Hospitalized Patients with Urinary Tract Infections (UTI) Due to Multidrug-Resistant Organisms (MDRO)
Frances J. Lahmann, DO; Margaret A. Olsen, PhD, MPH; Dustin Stewalley, MA; Jason P. Burnham, MD; Jennie H. Kwon, DO, MSC; Washington University in St. Louis School of Medicine, St. Louis, Missouri; 2Washington University in St. Louis; 3Washington, Saint Louis, Missouri; 4Washington University
Session: 157. Urinary Tract Infections
Friday, October 4, 2019: 12:15 PM
Background. Childhood urinary tract infection (UTI) may cause increased major morbidity and long-term clinical consequences. Extended-spectrum β-lactamase (ESBL) is produced by the members of the Enterobacteriaceae family, which are the primary infectious agents that cause UTI in children. Isolation of ESBL-producing Enterobacteriaceae (ESBL-E) typically occurred in healthcare facilities; however, the incidence of community-associated (CA) UTIs due to ESBL-E has increased world-wide. It has led to an increase in the use of carbapenems. In this study, we determine the characteristics of community-onset UTIs caused by ESBL-E in children to suggest non-carbapenem options for the treatment of childhood UTIs due to ESBL-E in order to preserve carbapenems.

Methods. A total of 2,157 isolates of ESBL-E were collected from children below 18 years old who were clinically certified UTI or urosepsis between January 2008 and August 2018 at tertiary university hospital in Korea. Their electronic medical records were retrospectively reviewed. Long-term healthcare facility stay within the preceding month and isolate recovered more than 72 hours after hospitalization were the criteria for healthcare-associated (HA) infection.

Results. The most common isolates were E. coli 1815 (84.2%) followed by K. pneumoniae 342 (15.8%). CA UTIs due to ESBL-E infection increased significantly from 68 cases in 2008 to 325 cases in 2017. Antibiotic susceptibility test showed highest sensitivity to etepenem, meropenem, and amikacin (>90%) followed by ceftoxitin (82%) and pipercillin–tazobactam (TZP) (80%). CA UTIs due to ESBL-E showed higher sensitivity to amikacin and TZP compared with HA E. coli. CA K. pneumoniae showed much higher sensitivity to TZP compared with HA K. pneumoniae. Of total ESBL-E, the antimicrobial resistance rate to aminoglycoside such as amikacin and gentamicin showed full sensitivity over the years.

Conclusion. Identifying antibiotic susceptibility patterns of ESBL-E is a useful guide for treatment strategy of UTI. This study showed that there are non-carbapenem options for the treatment of CA ESBL UTI in children.

Disclosures. All authors: No reported disclosures.